The purpose of the Pathology and Tissue Resource (PTR) Core is to provide comprehensive histology support, pathology support, and tumor and tissue resources to all five projects of this program. Pathology services will include tissue processing, slide preparation and staining, preparation of tissue arrays, laser capture microdissection, IHC assay development and analysis, in situ hybridization assays, BrdU staining, apoptosis (TUNEL) assays, and confocal microscopy and image analysis. As well as managing and providing access to existing tumor and tissue resources, the PTR Core will also assemble and maintain two new tissue resources that will be used by the projects. One is a retrospective bank of archival paraffin blocks of human invasive breast cancers with clinical follow-up to support prognostic/predictive studies, which will include approximately 2000 cases with extended follow-up, assembled into tissue arrays. The other is a retrospective bank of archival paraffin blocks of human premalignant breast lesions to support studies on the early development and progression to invasive breast cancer ? this bank will include approximately 1200 specimens, also assembled into tissue arrays. Overall, many thousands of blocks and slides will be prepared, stained, and evaluated over the duration of the Program. Performing the work in the PTR Core will ensure that it is done in the most expert, timely, and cost-efficient manner possible.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030195-23
Application #
7063041
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
23
Fiscal Year
2005
Total Cost
$170,059
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Pathiraja, Thushangi N; Nayak, Shweta R; Xi, Yuanxin et al. (2014) Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 6:229ra41
Zhang, Yi; Tseng, Chun-Chih; Tsai, Yuan-Li et al. (2013) Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 8:e80071
Machado, Heather L; Kittrell, Frances S; Edwards, David et al. (2013) Separation by cell size enriches for mammary stem cell repopulation activity. Stem Cells Transl Med 2:199-203
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Boone, David N; Lee, Adrian V (2012) Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 17:161-73
Casa, Angelo J; Potter, Adam S; Malik, Simeen et al. (2012) Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 132:61-73
Creighton, Chad J (2012) Molecular classification and drug response prediction in cancer. Curr Drug Targets 13:1488-94
Pathiraja, Thushangi N; Shetty, Priya B; Jelinek, Jaroslav et al. (2011) Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res 17:4177-86
Heckman-Stoddard, B M; Vargo-Gogola, T; Herrick, M P et al. (2011) P190A RhoGAP is required for mammary gland development. Dev Biol 360:1-10

Showing the most recent 10 out of 260 publications